Chemokine CCL2 and Its Receptor CCR2 in Different Age Groups of Patients with COVID-19

Overview

Journal BMC Immunol

Publisher Biomed Central

Specialty Allergy & Immunology

Date 2024 Oct 25

PMID 39455952

Authors

Vahid Bagheri

Hossein Khorramdelazad

Mehdi Kafi

Mitra Abbasifard

Affiliations

Soon will be listed here.

Abstract

Background: Despite the development of various antiviral drugs, most of them are not effective in the treatment of coronavirus disease 2019 (COVID-19) as a hyperinflammatory disorder. Chemokine (C-C motif) ligand 2 (CCL2) is one of the critical CC chemokines involved in the pathogenesis and severity of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. This study aimed to investigate the expression of CCL2 and CC chemokine receptor 2 (CCR2) in COVID-19 patients.

Methods: Peripheral blood samples were collected from 60 confirmed COVID-19 patients and 60 age-matched healthy subjects. The ages of the subjects were categorized as follows: up to 20 years, 20 to 40 years, 40 to 60 years, and more than 60 years. CCL2 serum levels were measured using the enzyme-linked immunosorbent assay (ELISA). CCR2 gene expression in peripheral blood mononuclear cells (PBMCs) was measured employing real-time polymerase chain reaction (PCR).

Results: In all age groups, CCL2 serum levels were significantly elevated in patients compared to healthy controls (P < 0.0001). CCL2 levels were higher in severe patients than in moderate patients. Moreover, CCR2 expression by PBMCs was higher in patients compared to control subjects. However, a significant difference between patients and controls over 60 years of age was identified (P = 0.0353). There was no significant difference in CCR2 expression between moderate and severe COVID-19 patients.

Conclusions: Taken together, the findings demonstrate that CCL2 and CCR2 are upregulated in COVID-19 patients at protein and mRNA levels, respectively. Therefore, the CCL2/CCR2 axis may be a potential therapeutic target in order to improve patient outcomes.

References

Sun J, He W, Wang L, Lai A, Ji X, Zhai X . COVID-19: Epidemiology, Evolution, and Cross-Disciplinary Perspectives. Trends Mol Med. 2020; 26(5):483-495. PMC: 7118693. DOI: 10.1016/j.molmed.2020.02.008. View

Abbasifard M, Khorramdelazad H . Harmonizing hope: navigating the osteoarthritis melody through the CCL2/CCR2 axis for innovative therapeutic avenues. Front Immunol. 2024; 15:1387651. PMC: 11284107. DOI: 10.3389/fimmu.2024.1387651. View

Xu Z, Shu T, Kang L, Wu D, Zhou X, Liao B . Temporal profiling of plasma cytokines, chemokines and growth factors from mild, severe and fatal COVID-19 patients. Signal Transduct Target Ther. 2020; 5(1):100. PMC: 7303571. DOI: 10.1038/s41392-020-0211-1. View

Li X, Yao W, Yuan Y, Chen P, Li B, Li J . Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma. Gut. 2015; 66(1):157-167. DOI: 10.1136/gutjnl-2015-310514. View

Rokni M, Hamblin M, Rezaei N . Cytokines and COVID-19: friends or foes?. Hum Vaccin Immunother. 2020; 16(10):2363-2365. PMC: 7644241. DOI: 10.1080/21645515.2020.1799669. View

Chen R, Lan Z, Ye J, Pang L, Liu Y, Wu W . Cytokine Storm: The Primary Determinant for the Pathophysiological Evolution of COVID-19 Deterioration. Front Immunol. 2021; 12:589095. PMC: 8115911. DOI: 10.3389/fimmu.2021.589095. View

Rokni M, Ghasemi V, Tavakoli Z . Immune responses and pathogenesis of SARS-CoV-2 during an outbreak in Iran: Comparison with SARS and MERS. Rev Med Virol. 2020; 30(3):e2107. PMC: 7235481. DOI: 10.1002/rmv.2107. View

Taghavi Y, Hassanshahi G, Kounis N, Koniari I, Khorramdelazad H . Monocyte chemoattractant protein-1 (MCP-1/CCL2) in diabetic retinopathy: latest evidence and clinical considerations. J Cell Commun Signal. 2019; 13(4):451-462. PMC: 6946768. DOI: 10.1007/s12079-018-00500-8. View

Winter C, Silvestre-Roig C, Ortega-Gomez A, Lemnitzer P, Poelman H, Schumski A . Chrono-pharmacological Targeting of the CCL2-CCR2 Axis Ameliorates Atherosclerosis. Cell Metab. 2018; 28(1):175-182.e5. DOI: 10.1016/j.cmet.2018.05.002. View

10.

Heidari Nia M, Rokni M, Mirinejad S, Kargar M, Rahdar S, Sargazi S . Association of polymorphisms in tumor necrosis factors with SARS-CoV-2 infection and mortality rate: A case-control study and in silico analyses. J Med Virol. 2021; 94(4):1502-1512. PMC: 9015227. DOI: 10.1002/jmv.27477. View

11.

Rokni M, Heidari Nia M, Sarhadi M, Mirinejad S, Sargazi S, Moudi M . Association of TMPRSS2 Gene Polymorphisms with COVID-19 Severity and Mortality: a Case-Control Study with Computational Analyses. Appl Biochem Biotechnol. 2022; 194(8):3507-3526. PMC: 8986508. DOI: 10.1007/s12010-022-03885-w. View

12.

Olivarria G, Lane T . Evaluating the role of chemokines and chemokine receptors involved in coronavirus infection. Expert Rev Clin Immunol. 2021; 18(1):57-66. PMC: 8851429. DOI: 10.1080/1744666X.2022.2017282. View

13.

Liao M, Liu Y, Yuan J, Wen Y, Xu G, Zhao J . Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nat Med. 2020; 26(6):842-844. DOI: 10.1038/s41591-020-0901-9. View

14.

Dawson T, Beck M, Kuziel W, Henderson F, Maeda N . Contrasting effects of CCR5 and CCR2 deficiency in the pulmonary inflammatory response to influenza A virus. Am J Pathol. 2000; 156(6):1951-9. PMC: 1850091. DOI: 10.1016/S0002-9440(10)65068-7. View

15.

Pum A, Ennemoser M, Adage T, Kungl A . Cytokines and Chemokines in SARS-CoV-2 Infections-Therapeutic Strategies Targeting Cytokine Storm. Biomolecules. 2021; 11(1). PMC: 7828218. DOI: 10.3390/biom11010091. View

16.

Ranjbar M, Rahimi A, Baghernejadan Z, Ghorbani A, Khorramdelazad H . Role of CCL2/CCR2 axis in the pathogenesis of COVID-19 and possible Treatments: All options on the Table. Int Immunopharmacol. 2022; 113(Pt A):109325. PMC: 9561120. DOI: 10.1016/j.intimp.2022.109325. View

17.

Xiong Y, Liu Y, Cao L, Wang D, Guo M, Jiang A . Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients. Emerg Microbes Infect. 2020; 9(1):761-770. PMC: 7170362. DOI: 10.1080/22221751.2020.1747363. View

18.

Azin H, Vazirinejad R, Nasiri Ahmadabadi B, Khorramdelazad H, Zarandi E, Arababadi M . The SDF-1 3'a genetic variation of the chemokine SDF-1α (CXCL12) in parallel with its increased circulating levels is associated with susceptibility to MS: a study on Iranian multiple sclerosis patients. J Mol Neurosci. 2011; 47(3):431-6. DOI: 10.1007/s12031-011-9672-6. View

19.

Khalil B, Elemam N, Maghazachi A . Chemokines and chemokine receptors during COVID-19 infection. Comput Struct Biotechnol J. 2021; 19:976-988. PMC: 7859556. DOI: 10.1016/j.csbj.2021.01.034. View

20.

Nile S, Nile A, Qiu J, Li L, Jia X, Kai G . COVID-19: Pathogenesis, cytokine storm and therapeutic potential of interferons. Cytokine Growth Factor Rev. 2020; 53:66-70. PMC: 7204669. DOI: 10.1016/j.cytogfr.2020.05.002. View